Information Provided By:
Fly News Breaks for February 5, 2020
Feb 5, 2020 | 05:03 EDT
Piper Sandler analyst Joseph Catanzaro upgraded Halozyme Therapeutics to Overweight from Neutral with a price target of $27, up from $18. With HALO-301 "now a distant memory," the analyst expects Darzalex subcutaneous will see "rapid and near complete conversion." His key opinion leader work suggests a 75% conversion one year after approval. The analyst expects Halozyme shares to outperform as the potential for "robust" Darzalex conversion is better appreciated.
News For HALO From the Last 2 Days
There are no results for your query HALO